Science Defies Politics

Silicon Valley is a Threat

COVID-19 Panel Gilead Ties

At least 7 (seven) members of the Panel on COVID-19 Treatment Guidelines, including 2 out of 3 Co-Chairs, have not disclosed their financial ties to Gilead Sciences (GILD), the patent owner and manufacturer of *remdesivir*.

Under the direction of WHO, *Remdesivir* is being tested as an alternative treatment to COVID-19. Currently, COVID-19 is treated by hydroxychloroquine (HCQ) with or without azithromycin (AZ).

Nine members of the Panel tasked with determining acceptable COVID-19 treatments have disclosed financial ties to Gilead, the manufacturer of *Remdesivir*. However, at least 7 other members failed to disclose their financial ties to Gilead and a number of other panel members appear to have links to Gilead that require no disclosure. Together, Gilead-linked individuals made up a majority of this panel.

This might explain why the panel recommended against a HCQ+AZ combination, refused to recommend HCQ ("insufficient clinical data to recommend either for or against") and raised fear, uncertainty, and doubt (FUD) about it. The Panel gave the same grade (but without FUD) to Remdesivir, though no clinical data existed for its use againstCOVID-19.

The list of the Panel members who have not disclosed their financial ties to Gilead is below. This is not an accusation against these individuals. The reporting period of Gilead ties was set to a mere 11 months (May 1, 2019 to March 31, 2020) and the last three weeks were excluded. The Guidelines were published on April 21 and already caused damage to the ongoing COVID-19 treatment.

Name	Financia	l Disclosure	Failed to Disclose
	Company	Relationship	
	None	N/A	Gilead Advisory Board, 2019
Jeffrey L.			https://aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_274.pdf
Lennox (*)			"Deleted" https://www.iasusa.org/blog/2018/11/19/primary-care-of-the-hiv-infected-adult-if-i-can-do-it-you-can-do-it-4/

Ann C. Collier	None	N/A	Past research support from Gilead (reported in 2013) https://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0065306
Roy M. Gulick, Co- Chair	None	N/A	Currently delivers lectures, funded with grants from Gilead https://www.prn.org/index.php/management/article/update_from_ias_amsterdam_part_1
John T. Brooks	None	N/A	Done HIV Conferences with Gilead Sciences (2018) https://ceitraining.org/courses/course_detail.cfm?mediaID=687
Henry Masur, Co- Chair	None	N/A	Gilead funded his research and conference(s), 2018 https://web.archive.org/web/20181204075041/https://www.iasusa.org/2018/02/22/welcometo-the-ias-usa-washington-dc-full-day-course-on-hiv-disease-management-2/ "Deleted" https://www.iasusa.org/blog/2018/11/15/recurring-and-emerging-questions-related-to-management-of-hiv-related-opportunistic-infections
Nitin Seam	None	N/A	Web Editorial Committee Chair with American Thoracic Society; Gilead is a Patron (2018) https://www.thoracic.org/about/resources/ats-annual-report-2018.pdf
Phyllis Tien	None	N/A	Research Grants by Gilead (2018) https://rsna2018.rsna.org/program/details/?publicid=SSC10-09

(*) Also, Jeffrey L. Lennox disclosed in 2009 that he "has been an investigator for Abbott, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Schering, and Tibotec; a paid consultant for Abbott, Gilead Sciences, Merck, Pfizer, Roche, and Tibotec; and a paid speaker for Abbott, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Roche, and Tibotec."

Please let me know if you find any errors in this table or the

accompanying description. If you are one of the people listed in the table , I will correct any error or publish your reply, or both. You can contact me by making a comment below (which will not be automatically published), or by email contact@defyccc.com.

P.S. Do NOT delete the linked pages. First, destruction of evidence is a crime. Second, do you really think that your website and the Web Archive are the only places where their copies exist?

Updated on April 27-28, 2020.

Related

Did Gilead Aid the Hit Job against HCQ?

April 23, 2020 In "-d"

How [we could not] Back to Normal, Stop COVID-19 March 17, 2020

In "-a"

Controlling COVID19

April 17, 2020

In "-a"